Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 222 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Norepinephrine Clear all
Terminated Phase 1 Interventional

Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

NCT01367990
View directory record Official record
Conditions
Alopecia, Radiodermatitis
Interventions
Norepinephrine
Drug
Lead sponsor
ProCertus BioPharm, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Phase 2 Interventional

Propranolol to Treat Fainting in Children With Sympathoadrenal Imbalance

NCT00093860
View directory record Official record
Conditions
Syncope
Interventions
Propranolol
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Phase 4 Interventional Results available

Norepinephrine vs Phenylephrine During General Anesthesia

NCT04789330
View directory record Official record
Conditions
Anesthesia, Surgery, Hypotension
Interventions
Norepinephrine, Phenylephrine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 99 Years
Enrollment
3,626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Not applicable Interventional

Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury

NCT00167856
View directory record Official record
Conditions
Neuropathic Pain, Pain, Spinal Cord Injuries
Interventions
Venalafaxine hydrochloride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Phase 4 Interventional

Relaxation Response Training for the Treatment of Rheumatoid Arthritis

NCT00056667
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Relaxation response and cognitive behavioral therapy, Relaxation response, RA education
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 18, 2026, 8:52 PM EDT
Completed No phase listed Observational

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

NCT03014063
View directory record Official record
Conditions
Septic Shock
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 18, 2026, 8:52 PM EDT
Not listed Phase 2 Interventional

Methylene Blue as a Third-line Vasopressor in Septic Shock

NCT04089072
View directory record Official record
Conditions
Septic Shock
Interventions
Methylene Blue, Phenylephrine
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Phase 2 Interventional

Induced Hypertension for Acute Ischemic Stroke

NCT00227448
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
intravenous saline, intravenous phenylephrine, intravenous levophed, oral midodrine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 18, 2026, 8:52 PM EDT
Withdrawn Phase 4 Interventional

Duloxetine Tibial Plateau

NCT04639011
View directory record Official record
Conditions
Tibial Plateau Fracture, Pain, Postoperative
Interventions
Duloxetine, Placebo, Standard of care (SOC) for tibial plateau surgery
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 18, 2026, 8:52 PM EDT
Active, not recruiting Phase 3 Interventional

Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests

NCT03539614
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Prazosin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Early Phase 1 Interventional

Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg

NCT02789150
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Norepinephrine (Levophed)
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 18, 2026, 8:52 PM EDT
Recruiting Phase 4 Interventional

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures

NCT05851898
View directory record Official record
Conditions
Depression in Old Age, Fragility Fracture
Interventions
Duloxetine 30 mg
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 18, 2026, 8:52 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy

NCT01544504
View directory record Official record
Conditions
Radiodermatitis
Interventions
Norepinephrine
Drug
Lead sponsor
ProCertus BioPharm, Inc
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With Depression

NCT04039022
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Depression
Interventions
AXS-05 (dextromethorphan and bupropion) oral tablets
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

NCT04843761
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 18, 2026, 8:52 PM EDT
Recruiting Not applicable Interventional

Algorithm-informed Decision-making to Advance Pain Treatment

NCT07731750
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Algorithmically informed randomization (taking into account phenotypes), Physical Therapy (PT) and Exercise, Cognitive-Behavioral Therapy for Pain (PRISM-CBT), mHealth Acupressure Self-Management:, Duloxetine
Device · Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 18, 2026, 8:52 PM EDT
Terminated Phase 4 Interventional Results available

Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients

NCT02203630
View directory record Official record
Conditions
Septic Shock, Sepsis, Shock, Tachycardia, Arrhythmia
Interventions
Phenylephrine, Norepinephrine
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 18, 2026, 8:52 PM EDT
Recruiting Phase 3 Interventional

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

NCT06568367
View directory record Official record
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Auburn, Alabama • Cullman, Alabama • Chandler, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 18, 2026, 8:52 PM EDT
Completed No phase listed Observational

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

NCT06049797
View directory record Official record
Conditions
Hot Flashes
Interventions
Fezolinetant, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05455684
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
46
States / cities
Tucson, Arizona • Anaheim, California • Culver City, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Local Antioxidant Therapy Vasoconstriction Effects in Different Races

NCT03684213
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions
Control (Norepinephrine), Norepinephrine + Ascorbic Acid, Norepinephrine + L-NAME, Norepinephrine + L-NAME + Ascorbic Acid
Drug
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 35 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Phase 4 Interventional Results available

Sequenced Treatment Effectiveness for Posttraumatic Stress

NCT04597190
View directory record Official record
Conditions
PTSD
Interventions
Selective serotonin reuptake inhibitor, Serotonin-norepinephrine reuptake inhibitor, Written Exposure Therapy
Drug · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
North Little Rock, Arkansas • West Memphis, Arkansas • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 18, 2026, 8:52 PM EDT
Completed Early Phase 1 Interventional

Vasopressor Outcomes in Spine Surgery

NCT06053398
View directory record Official record
Conditions
Hypotension
Interventions
Phenylephrine, Norepinephrine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 18, 2026, 8:52 PM EDT
Enrolling by invitation Phase 3 Interventional

Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

NCT07637162
View directory record Official record
Conditions
Fibromyalgia
Interventions
AXS-14 (esreboxetine)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
35
States / cities
Little Rock, Arkansas • Oceanside, California • Redlands, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 8:52 PM EDT